Free Trial
NASDAQ:NMTR

9 Meters Biopharma (NMTR) Stock Price, News & Analysis

9 Meters Biopharma logo

About 9 Meters Biopharma Stock (NASDAQ:NMTR)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
315,915 shs
Market Capitalization
$1.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Remove Ads
Receive NMTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

NMTR Stock News Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
9 Meters Biopharma, Inc. (NMTRQ)
9 Meters Biopharma Inc (NMTRQ)
9 Meters Biopharma (OTC: NMTR.Q)
See More Headlines

NMTR Stock Analysis - Frequently Asked Questions

9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings data on Monday, November, 15th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.26.

9 Meters Biopharma shares reverse split on the morning of Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 9 Meters Biopharma investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), SNDL (SNDL), NIO (NIO), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/15/2021
Today
4/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NMTR
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-43,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
N/A

Miscellaneous

Free Float
13,992,000
Market Cap
$1.04 million
Optionable
No Data
Beta
1.36
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:NMTR) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners